Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Here's what's new in Bay Area biz news to start your workweek: tech stocks on wild ride, empty S.F. office buildings, copper ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...

(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...

The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...

Sionna Therapeutics and Odyssey Therapeutics join Metsera and Maze in filing for IPOs, with Sionna focused on cystic fibrosis ...